NCT02091921View on ClinicalTrials.gov

Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 16, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Critical Limb Ischemia
Interventions
DRUG

Ticagrelor

All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.

Trial Locations (1)

90033

University of Southern California, Los Angeles

All Listed Sponsors
lead

University of Southern California

OTHER

NCT02091921 - Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study | Biotech Hunter | Biotech Hunter